CX717

10/01/2012 - "The ampakine CX717 markedly reduced the severity of respiratory depression."
10/01/2012 - "Administration of the ampakine CX717 alleviated a significant component of the respiratory depression in vitro (50-150 μM) and in vivo (30 mg/kg ip). "
06/01/2013 - "In vitro, respiratory depression caused by propofol (2 μM, n = 11, mean ± SEM, 41 ± 5% of control frequency, 63 ± 5% of control duration) was alleviated by CX717 (n = 4, 50-150 μM). "
10/01/2012 - "Respiratory depression in rats induced by alcohol and barbiturate and rescue by ampakine CX717."
06/01/2009 - "Preadministration of CX717 markedly attenuated fentanyl-induced respiratory depression. "

09/01/2005 - "The ampakine CX717, in addition to enhancing cognitive performance under normal alert conditions, also proved effective in alleviating impairment of performance due to sleep deprivation. "
08/01/2012 - "The study suggests that CX717 only at the 1000 mg dose may counteract effects of sleep deprivation on attention-based tasks and that it may interfere with subsequent recovery sleep."
08/01/2012 - "Acute sleep deprivation: the effects of the AMPAKINE compound CX717 on human cognitive performance, alertness and recovery sleep."
01/01/2009 - "Sleep deprivation in NHPs produced impaired performance and reductions in brain activation which was reversed by CX717. "
09/01/2005 - "Facilitation of task performance and removal of the effects of sleep deprivation by an ampakine (CX717) in nonhuman primates."

06/01/2009 - "The effective dose of CX717 was in the range deemed safe on the basis of clinical trials examining its efficacy for cognitive disorders. "

10/01/2007 - "Further work evaluating higher doses of CX717 may be warranted, as are studies in which CX717 effects are explored under other conditions (e.g., Alzheimer's dementia, attention deficit disorder)."

10/01/2007 - "Further work evaluating higher doses of CX717 may be warranted, as are studies in which CX717 effects are explored under other conditions (e.g., Alzheimer's dementia, attention deficit disorder)."